%PDF-1.4
%
28 0 obj
<>
endobj
25 0 obj
<>
endobj
149 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-12-14T13:10:49Z
2024-03-29T05:10:37-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-29T05:10:37-07:00
application/pdf
Heather
2002-65.oct
uuid:0769ba94-1dd2-11b2-0a00-d308275d6100
uuid:0769ba96-1dd2-11b2-0a00-aa0000000000
endstream
endobj
14 0 obj
<>
endobj
15 0 obj
<>
endobj
29 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
7 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
166 0 obj
[171 0 R]
endobj
167 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/TT0 1 Tf
-0.0278 Tw 10 0 0 10 54 713.1616 Tm
[(good surrogate of disease activity is most required. )18 (The clin-)]TJ
0.0284 Tw 0 -1.2 TD
(ician needs a guide by which to adjust therapy from visit to)Tj
-0.00999 Tw T*
(visit to give the best chance of preserved structure and func-)Tj
-0.0361 Tw T*
(tion over the decades of this persistent disease. Patients want)Tj
0.05969 Tw T*
(to know that their agreement to more aggressive therapy is)Tj
0.37019 Tw T*
(justified by the evidence backing the longterm conse-)Tj
0.1223 Tw T*
[(quences of alternative decisions. )18 (T)35 (ime then to expand our)]TJ
0.04131 Tw T*
(clinical research, to start trials of a new kind, prospectively)Tj
0.008 Tc 0.367 Tw T*
[(designed randomized controlled trials that test tar)18 (gets)]TJ
0 Tc 0.02499 Tw T*
(against outcomes.)Tj
/TT1 1 Tf
-0.00011 Tc 0 -2.4 TD
(JOHN EDMONDS,)Tj
/TT0 1 Tf
6 0 0 6 140.8794 581.1616 Tm
[(MB, BS, MA, FRACP)111 (,)]TJ
8 0 0 8 54 571.1616 Tm
[(Professor of Rheumatology)65 (,)]TJ
0 -1.25 TD
[(University of New South )18 (W)80 (ales,)]TJ
0 Tc T*
[(Director of Rheumatology)65 (,)]TJ
T*
[(St. Geor)18 (ge Hospital, Sydney;)]TJ
/TT1 1 Tf
-0.00011 Tc 0 Tw 10 0 0 10 54 529.1616 Tm
[(MARISSA)-220 (LASSERE,)]TJ
/TT0 1 Tf
0.02499 Tw 6 0 0 6 153.1206 529.1616 Tm
[(MB, BS \(Hons\), Grad Dip Epi, PhD, FRACP)111 (, F)74 (AFPHM,)]TJ
0 Tc 8 0 0 8 54 519.1616 Tm
(Senior Lecturer in Medicine,)Tj
-0.00011 Tc T*
[(University of New South )18 (W)80 (ales 2217,)]TJ
0 Tc T*
(Senior Lecturer in Public Health and Community Medicine, )Tj
-0.00011 Tc T*
[(Sydney University)65 (,)]TJ
0 Tc T*
[(Staf)18 (f Specialist in Rheumatology)65 (,)]TJ
T*
[(St. Geor)18 (ge Hospital, Sydney)65 (, )55 (Australia.)]TJ
/TT2 1 Tf
-0.00011 Tc 0.06419 Tw 0 -2.75 TD
[(Addr)37 (ess r)37 (eprint r)37 (equests to Pr)37 (of. Edmonds)]TJ
/TT0 1 Tf
0 Tc 0 Tw 17.282 0 Td
(, )Tj
/TT2 1 Tf
0.06419 Tw 0.5643 0 Td
[(Department of Rheumatology)55 (,)]TJ
0.0249 Tw -17.8463 -1.25 Td
[(Gray Str)37 (eet, Kogarah, NSW 2217, )18 (Australia.)]TJ
/TT1 1 Tf
-0.00011 Tc 0 Tw 10 0 0 10 54 413.1616 Tm
(REFERENCES)Tj
/TT0 1 Tf
0 Tc 0.02499 Tw 8 0 0 8 61 403.1616 Tm
[(1.)-875 (Strand )18 (V)129 (, Cohen S, Schif)18 (f M, et al. )18 (T)35 (reatment of active rheumatoid)]TJ
1.675 -1.25 Td
(arthritis with leflunomide compared with placebo and methotrexate.)Tj
0 -1.25 TD
(Arch Intern Med 1999;159:2542-50.)Tj
-1.675 -1.25 Td
[(2.)-875 (Smolen JS, Kalden JR, Scott DL, et al. Ef)18 (ficacy and safety of)]TJ
1.675 -1.25 Td
(leflunomide compared with placebo and sulphasalazine in active)Tj
T*
(rheumatoid arthritis: a double-blind, randomised, multicentre trial.)Tj
T*
(Lancet 1999;353:259-66.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(3.)-875 (Bathon JM, Martin R)55 (W)92 (, Fleischmann RM, et al. )55 (A)-220 (comparison of)]TJ
0 Tc 1.675 -1.25 Td
(etanercept and methotrexate in patients with early rheumatoid)Tj
T*
(arthritis. New Engl J Med 2000;343:1586-93.)Tj
-1.675 -1.25 Td
[(4.)-875 (Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind)]TJ
1.675 -1.25 Td
(comparison of chimeric monoclonal antibody to tumour necrosis)Tj
-0.00011 Tc T*
(factor \(cA2\) versus placebo in rheumatoid arthritis. Lancet)Tj
0 Tc 0 Tw T*
[(1994;344:1)37 (105-10.)]TJ
0.02499 Tw -1.675 -1.25 Td
[(5.)-875 (V)111 (an de Putte LBA, Rau R, Breedveld FC, et al. One year ef)18 (ficacy)]TJ
1.675 -1.25 Td
(results of the fully human anti-TNF antibody D2E7 in rheumatoid)Tj
T*
[(arthritis [abstract]. )55 (Arthritis Rheum 2000;43 Suppl:S269.)]TJ
-0.00011 Tc -1.675 -1.25 Td
[(6.)-875 (Bresnihan B, )55 (Alvaro-Garcia JM, Cobby M, et al. )18 (T)35 (reatment of)]TJ
0 Tc 1.675 -1.25 Td
(rheumatoid arthritis with recombinant human interleukin-1 receptor)Tj
T*
[(antagonist. )55 (Arthritis Rheum 1998;41:2196-204.)]TJ
-0.00011 Tc -1.675 -1.25 Td
[(7.)-875 (Hansson L, Zanchetti )55 (A, Carruthers SG, et al. Ef)18 (fects of intensive)]TJ
1.675 -1.25 Td
(blood-pressure lowering and low dose aspirin in patients with)Tj
0 Tc T*
(hypertension: principal results of the Hypertension Optimal)Tj
T*
[(T)35 (reatment \(HOT\) randomised trial. Lancet 1998;351:1755-62.)]TJ
-1.675 -1.25 Td
[(8.)-875 (W)80 (orld Health Or)18 (ganization-International Society of Hypertension.)]TJ
1.675 -1.25 Td
[(Guidelines Subcommittee. 1999 )18 (WHO-ISH guidelines for the)]TJ
T*
(management of hypertension. J Hypertens 1999;17:151-83.)Tj
-0.00011 Tc 31.325 71.421 Td
[(9.)-875 (UK Prospective Diabetes Study \(UKPDS\) Group. Intensive blood)]TJ
0 Tc 1.675 -1.25 Td
(glucose control with sulphonylureas or insulin compared with)Tj
T*
(conventional treatment and risk complications in patients with type)Tj
T*
(2 diabetes \(UKPDS 33\). Lancet 1998;352:837-53.)Tj
-2.175 -1.25 Td
[(10.)-875 (Fleming )18 (TR, DeMets DL. Surrogate end points in clinical trials: are)]TJ
2.175 -1.25 Td
[(we being misled? )55 (Ann Intern Med 1996;125:605-13.)]TJ
-2.1381 -1.25 Td
[(1)37 (1.)-875 (Psaty BM, )18 (W)80 (eiss NS, Furber)18 (g CD, et al. Surrogate end points,)]TJ
2.1381 -1.25 Td
(health outcomes, and the drug-approval process for the treatment of)Tj
-0.00011 Tc T*
[(risk factors for cardiovascular disease. JAMA)-220 (1999;282:786-90.)]TJ
-2.175 -1.25 Td
[(12.)-875 (The )55 (ALLHA)111 (T)-257 (Of)18 (ficers and Coordinators for the )55 (ALLHA)111 (T)]TJ
0 Tc 2.175 -1.25 Td
(Collaborative Research Group. Major cardiovascular events in)Tj
T*
(hypertensive patients randomized to doxazosin vs chlorthalidone.)Tj
T*
[(The )55 (Antihypertensive and Lipid-Lowering treatment to prevent)]TJ
-0.00011 Tc -0.0298 Tw T*
[(Heart Attack )-37 (T)35 (rial )-55 (\(ALLHA)111 (T\). )-55 (JAMA)-220 (2000;283:1967-75.)]TJ
0.02499 Tw -2.175 -1.25 Td
[(13.)-875 (Furber)18 (g CD, Psaty BM, Pahor M, )55 (Alderman MH. Clinical)]TJ
0 Tc 2.175 -1.25 Td
(implications of recent findings from the antihypertensive and lipid)Tj
T*
[(lowering treatment to prevent heart attack trial \(ALLHA)111 (T\) and)]TJ
T*
[(other studies of hypertension. )55 (Ann Intern Med 2001;135:1074-8.)]TJ
-2.175 -1.25 Td
[(14.)-875 (Kaplan NM. Management of hypertension in patients with type 2)]TJ
2.175 -1.25 Td
[(diabetes mellitus: guidelines based on current evidence. )55 (Ann Intern)]TJ
T*
(Med 2001;135:1079-83.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(15.)-875 (Pinals RS, Masi )55 (A)111 (T)74 (, Larsen RA, et al. Preliminary criteria for)]TJ
0 Tc 2.175 -1.25 Td
[(clinical remission in rheumatoid arthritis. )55 (Arthritis Rheum)]TJ
0 Tw T*
(1981;24:1308-15.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(16.)-875 (W)80 (olfe F)80 (, Ross K, Hawley DJ, et al. )18 (The prognosis of RA)-220 (and)]TJ
0 Tc 2.175 -1.25 Td
[(undif)18 (ferentiated polyarthritis syndrome in the clinic: a study of 1)37 (14)]TJ
T*
(patients. J Rheumatol 1993;20:2005-9.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(17.)-875 (Suarez-Almazor M, Soskolne CL, Saunders LD, Russell )55 (AS.)]TJ
0 Tc 2.175 -1.25 Td
[(Outcome of RA. )55 (A)-220 (1985 inception cohort study)65 (. J Rheumatol)]TJ
0 Tw T*
(1994;21:1438-46.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(18.)-875 (Felson DT)74 (, )55 (Anderson JJ, Boers M, et al. )18 (The )55 (American College of)]TJ
0 Tc 2.175 -1.25 Td
(Rheumatology preliminary core set of disease activity measures for)Tj
T*
[(rheumatoid arthritis clinical trials. )55 (Arthritis Rheum 1993;36:729-40.)]TJ
-2.175 -1.25 Td
[(19.)-875 (van Gestel )55 (AM, Prevoo MLL, van\222)18 (t Hof MA, et al. Development)]TJ
2.175 -1.25 Td
[(and validation of the European League )55 (Against Rheumatism)]TJ
-0.00011 Tc T*
[(response criteria for rheumatoid arthritis. )55 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1996;39:34-40.)Tj
0.0249 Tw -2.175 -1.25 Td
[(20.)-875 (Spiegel )18 (TM, Spiegel JS, Paulus HE. )18 (The Joint )55 (Alignment and)]TJ
2.175 -1.25 Td
[(Motion Scale: )55 (A)-220 (simple measure of joint deformity in patients with)]TJ
T*
(rheumatoid arthritis. J Rheumatol 1987;14:887-92.)Tj
-2.175 -1.25 Td
[(21.)-875 (V)111 (an der Heijde D, Lassere M, Edmonds J, et al. Minimal clinically)]TJ
-0.00011 Tc 2.175 -1.25 Td
[(important dif)18 (ferences in plain films in RA: group discussions,)]TJ
0 Tc T*
(conclusions and recommendations. J Rheumatol 2001;28:914-7.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(22.)-875 (McQueen FM, Stewart N, Crabbe J, et al. Magnetic resonance)]TJ
0 Tc 2.175 -1.25 Td
(imaging of the wrist in early rheumatoid arthritis reveals a high)Tj
T*
[(prevalence of erosions at four months after symptom onset. )55 (Ann)]TJ
T*
(Rheum Dis 1998;57:350-6.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(23.)-875 (V)111 (an Leeuwen MA, van Rijswijk MH, Sluiter )18 (WJ, et al. Individual)]TJ
0 Tc 2.175 -1.25 Td
(relationship between progression of radiological damage and the)Tj
T*
[(acute phase response in early RA. )18 (T)70 (owards development of a)]TJ
T*
(decision support system. J Rheumatol 1997;24:20-7.)Tj
-2.175 -1.25 Td
[(24.)-875 (Boers M, Kostense PJ, )18 (V)111 (erhoeven )55 (AC, et al. Inflammation and)]TJ
2.175 -1.25 Td
(damage in an individual joints predict further damage in that joint)Tj
T*
[(in patients with early rheumatoid arthritis. )55 (Arthritis Rheum)]TJ
0 Tw T*
(2001;44:2242-46l.)Tj
/TT2 1 Tf
0.02499 Tw 10.24516 -17.31815 Td
(The Journal of Rheumatology 2002; 29:10)Tj
0 Tw -45.7952 -0.0313 Td
(2044)Tj
ET
Q
Q
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
/CS1 CS 0 0 0 1 SCN
/GS1 gs
54 54 m
558 54 l
S
Q
Q
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
/CS1 cs 0 0 0 0 scn
104.25 58.54 407.5 -10.83 re
f*
Q
Q
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
/CS1 CS 0 0 0 1 SCN
0.5 w
104.25 58.54 407.5 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
ET
/GS2 gs
BT
/T1_0 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2002. All rights reserved.)Tj
ET
Q
BT
0 g
/GS3 gs
/T1_1 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS3 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS3 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
100 0 obj
<>
endobj
155 0 obj
<>
endobj
33 0 obj
<>
endobj
10 0 obj
<>
endobj
31 0 obj
<>
endobj
32 0 obj
<>
endobj
63 0 obj
<>stream
HV pUBBr@6dGI`$ 9@$TJdȢ˲b Ұ&lQ@-rEɱED$h˗u@ h(bF/I瀼&jW+g])0f W-ZM6rfŤC(9KU%d./z䞾TD
O(w+XKgϗoj~tJ͔#*+ósJE6߸5ӯrmZ0nm_ZwLZdm!YGVJ.-b,54;R*Ix~w\yN$P_*OA}KX=8s(aYoAOSCU1
ZkH50S9*
YgmB3'ᢋp Qy